Brief: Cytokinetics Q1 Basic EPS USD -1.67
05/05/2026 21:05
May 05 (Reuters) - Cytokinetics Q1 R&D revenue USD 4.789 million. Q1 operating expenses USD 202.973 million Q1 net income USD -206.031 million Q1 operating income USD -183.618 million
Recent news on Cytokinetics, Incorporated
See all newsBrief: Cytokinetics To Announce Third Quarter Results On November 4, 2026
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Cytokinetics Announces Additional Data From Acacia-Hcm Presented At The Hfsa Annual Scientific Meeting 2026
Brief: Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech